A phase I and pharmacokinetic study of the selective, non-peptidic inhibitor of matrix metalloproteinase BAY 12-9566 in combination with etoposide and carboplatin

Anti-Cancer Drugs

Volumn 16, Issue 9, 2005, Pages 997-1002

  Molina, Julian R ^a   Reid, Joel M ^a   Erlichman, Charles ^a   Sloan, Jeff A ^a   Furth, Alfred ^a   Safgren, Stephanie L ^a   Lathia, Chetan D ^b   Alberts, Steven R ^a  

^a MAYO CLINIC   (United States)

^b BAYER CORPORATION   (United States)

Author keywords

BAY 12 9566; Chemotherapy; Hematologic toxicity; Metalloproteinase inhibitors

Indexed keywords

CARBOPLATIN; ETOPOSIDE; MATRIX METALLOPROTEINASE INHIBITOR; TANOMASTAT;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MELANOMA; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA; THYMOMA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ALOPECIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; COHORT STUDIES; COLONIC NEOPLASMS; ENZYME INHIBITORS; ETOPOSIDE; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASES; MELANOMA; MIDDLE AGED; NEOPLASMS; NEOPLASMS, UNKNOWN PRIMARY; NEUTROPENIA; ORGANIC CHEMICALS; THROMBOCYTOPENIA; THYMOMA; TREATMENT OUTCOME; VOMITING;

EID: 26244435100     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000176504.86551.5c     Document Type: Article

References (17)

1. Wojtowictz-Praga SM, Dickson RB, Hawkins MJ. Matrix metalloproteinase inhibitors. Invest New Drugs 1997; 15:61-75.
2. Bull C, Flynn C, Eberwein D, Cosazza A, Carter CA, Hibner B. Activity of the biphenyl matrix metalloproteinase inhibitor BAY 12-9566 in murine in vivo models. Proc Am Ass Cancer Res 1998; 39: 302 (abstr 2062).
3. Flynn C, Bull C, Matherne C, Eberwein N, Gibson B, Hibner B. Invasive and anti-metastatic activity of the novel MMP inhibitor BAY 12-9566 in subcutaneous and orthotopic models using the human colon carcinoma, HCT. Ann Oncol 1998; 9 (Suppl 2): 75 (abstr).
4. Flynn C, Bull C, Matherne C, Hibner B. Anti-metastatic activity of BAY12-9566 in a human colon carcinoma HCT 116 orthotopic model. Proc Am Ass Cancer Res 1998; 39:2057.
5. Nozaki S, Sissons S, Casazza AM. Inhibition of human breast cancer regrowth and pulmonary metastasis by BAY 12-9566 in athymic mice. Proc Am Ass Cancer Res 1998; 39:301.
6. Hibner B, Gard A, Flynn C. BAY 12-9566, a novel biphenyl matrix metalloproteinase inhibitor demonstrates anti-invasive and anti-angiogenic properties. Proc Am Ass Cancer Res 1998; 39:302.
7. Rowinsky EK, Humphrey R, Hammond LA, Aylesworth C, Smetzer L, Hidalgo M, et al. Phase I and pharmacokinetic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies. J Clin Oncol 2000; 18:178-186.
8. Erlichman C, Adjei A, Alberts S, Sloan JA, Goldberg RM, Pilot HC, et al. Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566. Ann Oncol 2001; 12:389-395.
9. Goel R, Hirtle H, Shah A. Phase I study of the metalloproteinase inhibitor Bayer 12-9566. Proc Am Soc Clin Oncol 1998; 17:217a.
10. Grochow L, O'Reilly S, Humprey R. Phase I and pharmacokinetic study of the matrix metalloproteinase inhibitor (MMPI) Bay 12-9566. Proc Am Soc Clin Oncol 1998; 17: 217a.
11. Heath EI, O'Reilly S, Sundaresan P, Donehower RC, Sartorius S, Kennedy MJ, et al. Phase I trial of the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced solid tumors. Cancer Chemother Pharmacol 2001; 48:269-274.
12. Goel R, Chouinard E, Stewart DJ, Huan S, Hirte H, Stafford S, et al. An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/ leucovorin. Invest New Drugs 2005; 23:63-71.
13. Thall PF, Simon RM, Estey EH. New statistical strategy for monitoring safety and efficacy in single arm clinical trials. J Clin Oncol 1996; 14:296-303.
14. Sinkule JA, Evans WE. High-performance liquid chromatographic analysis of the semisynthetic epipodophyllotoxins teniposide and etoposide using electrochemical detection. J Pharm Sci 1984; 73:164-168.
15. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 2001; 93:178-193.
16. Hirte H, Setwart D, Goel R, Chouinard E, Huan S, Stafford S, et al. An NCIC-CTG phase I dose escalation pharmacokinetic study of the matrix metalloproteinase inhibitor BAY 12-9566 in combination with doxorubicin. Invest New Drugs 2005; in press.
17. Tolcher A, Rowinsky EK, Rizzo J, Britten C, Siu L, Humprey R, et al. A phase I and pharmacokinetic study of the oral matrix metalloproteinase inhibitor BAY 12-9566 in combination with paclitaxel and carboplatin. Proc Am Soc Clin Oncol 1999; 18:160a.